Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Reduce" from Analysts

Key Points

• Y-mAbs Therapeutics, Inc. has received a consensus rating of "Reduce" from ten brokerages, with two issuing sell ratings and eight assigning a hold rating.
• The average twelve-month target price for the stock is $9.62, while recent analyses from various firms set the target at $8.60.
• In its latest earnings report, Y-mAbs reported earnings per share of ($0.07), surpassing consensus estimates and generating revenue of $19.52 million.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been given a consensus rating of "Reduce" by the ten brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $9.6222.

A number of analysts recently issued reports on YMAB shares. Truist Financial set a $8.60 target price on Y-mAbs Therapeutics in a research note on Tuesday, August 5th. HC Wainwright reaffirmed a "neutral" rating and set a $8.60 price target (down from $11.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday, August 6th. Morgan Stanley set a $8.60 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Oppenheimer cut shares of Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 5th. Finally, Brookline Capital Management cut shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its stake in Y-mAbs Therapeutics by 59.5% in the fourth quarter. Bank of America Corp DE now owns 127,159 shares of the company's stock valued at $996,000 after purchasing an additional 47,439 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Y-mAbs Therapeutics by 107.9% during the first quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock worth $119,000 after purchasing an additional 13,890 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Y-mAbs Therapeutics by 17.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock worth $410,000 after purchasing an additional 7,765 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 822,309 shares of the company's stock worth $6,440,000 after purchasing an additional 8,820 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ:YMAB opened at $8.53 on Friday. Y-mAbs Therapeutics has a 52 week low of $3.55 and a 52 week high of $16.11. The company's fifty day moving average is $5.66 and its 200-day moving average is $5.12. The company has a market capitalization of $387.60 million, a PE ratio of -17.06 and a beta of 0.57.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Friday, August 8th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.20. The business had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative return on equity of 24.60%. On average, analysts forecast that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.